HUTCHMED (China) Limited 0013.HK Stock
HUTCHMED (China) Limited Price Chart
HUTCHMED (China) Limited 0013.HK Financial and Trading Overview
HUTCHMED (China) Limited stock price | 28.25 HKD |
Previous Close | 30.15 HKD |
Open | 30.1 HKD |
Bid | 30.25 HKD x N/A |
Ask | 30.35 HKD x N/A |
Day's Range | 29.4 - 30.6 HKD |
52 Week Range | 17.44 - 33.8 HKD |
Volume | 1.71M HKD |
Avg. Volume | 3.38M HKD |
Market Cap | 26.44B HKD |
Beta (5Y Monthly) | 0.755 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.94 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0013.HK Valuation Measures
Enterprise Value | 24.95B HKD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 34.91659 |
Price/Book (mrq) | 32.917572 |
Enterprise Value/Revenue | 32.944 |
Enterprise Value/EBITDA | -273.576 |
Trading Information
HUTCHMED (China) Limited Stock Price History
Beta (5Y Monthly) | 0.755 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 33.8 HKD |
52 Week Low | 17.44 HKD |
50-Day Moving Average | 28.98 HKD |
200-Day Moving Average | 24.09 HKD |
0013.HK Share Statistics
Avg. Volume (3 month) | 3.38M HKD |
Avg. Daily Volume (10-Days) | 3.49M HKD |
Shares Outstanding | 871.17M |
Float | 508.01M |
Short Ratio | N/A |
% Held by Insiders | 42.94% |
% Held by Institutions | 35.34% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -3.88% |
Operating Margin (ttm) | 20.95% |
Gross Margin | 3.34% |
EBITDA Margin | -12.041% |
Management Effectiveness
Return on Assets (ttm) | -4.98% |
Return on Equity (ttm) | -3.39% |
Income Statement
Revenue (ttm) | 757.24M HKD |
Revenue Per Share (ttm) | 0.9 HKD |
Quarterly Revenue Growth (yoy) | 163.69% |
Gross Profit (ttm) | -271587000 HKD |
EBITDA | -91185000 HKD |
Net Income Avi to Common (ttm) | -29423000 HKD |
Diluted EPS (ttm) | -0.39 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 858.44M HKD |
Total Cash Per Share (mrq) | 1.01 HKD |
Total Debt (mrq) | 40.15M HKD |
Total Debt/Equity (mrq) | 5.02 HKD |
Current Ratio (mrq) | 3.199 |
Book Value Per Share (mrq) | 0.922 |
Cash Flow Statement
Operating Cash Flow (ttm) | 47.66M HKD |
Levered Free Cash Flow (ttm) | -91008128 HKD |
Profile of HUTCHMED (China) Limited
Country | Hong Kong |
State | N/A |
City | Central |
Address | Cheung Kong Center |
ZIP | N/A |
Phone | 852 2121 8200 |
Website | https://www.hutch-med.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 1990 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Q&A For HUTCHMED (China) Limited Stock
What is a current 0013.HK stock price?
HUTCHMED (China) Limited 0013.HK stock price today per share is 28.25 HKD.
How to purchase HUTCHMED (China) Limited stock?
You can buy 0013.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HUTCHMED (China) Limited?
The stock symbol or ticker of HUTCHMED (China) Limited is 0013.HK.
Which industry does the HUTCHMED (China) Limited company belong to?
The HUTCHMED (China) Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does HUTCHMED (China) Limited have in circulation?
The max supply of HUTCHMED (China) Limited shares is 853.64M.
What is HUTCHMED (China) Limited Price to Earnings Ratio (PE Ratio)?
HUTCHMED (China) Limited PE Ratio is 30.05319200 now.
What was HUTCHMED (China) Limited earnings per share over the trailing 12 months (TTM)?
HUTCHMED (China) Limited EPS is 0.94 HKD over the trailing 12 months.
Which sector does the HUTCHMED (China) Limited company belong to?
The HUTCHMED (China) Limited sector is Healthcare.
Stocks Related By Sector
- Shanghai Junshi Biosciences Co., Ltd. 1877.HK Stock
- Shandong Weigao Group Medical Polymer Company Limited 1066.HK Stock
- China Traditional Chinese Medicine Holdings Co. Limited 0570.HK Stock
- Hygeia Healthcare Holdings Co., Limited 6078.HK Stock
- The United Laboratories International Holdings Limited 3933.HK Stock